🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Liver Cancer

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment NCT05661461Phase 12 sites📍 San Antonio📍 West Valley City Aadi Bioscience, Inc. · Tests: nab-sirolimus Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation NCT06718153NA1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Immunohistochemistry and in situ hybridisation analysis FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Durvalumab, Bevacizumab, HAIC of FOLFOX The Development of MASLD Among Survivors of Breast or Colorectal Cancer NCT07280143n/a1 site📍 Bern University of Bern Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention NCT07010315n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Cognitive Testing, Usability Testing Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) NCT06561399n/a4 sites📍 Fuzhou📍 Fuzhou📍 Fuzhou Fujian Provincial Hospital · Tests: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT07832006Phase 21 site📍 Beijing Shunda Du · Tests: Irreversible Electroporation, Lenvatinib, Sintilimab The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors NCT07159048NA1 site📍 Shanghai Fudan University · Tests: Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC NCT07658833n/a1 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: TACE (transarterial chemoembolization) combined with targeted/immunotherapy Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663Phase 2, Phase 31 site📍 Shanghai RenJi Hospital · Tests: [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4 Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876NA1 site📍 Beijing Sun Yat-sen University · Tests: Thermal ablation, Donafenib Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma NCT05047510NA2 sites📍 Zhuhai📍 Luzhou Chinese Academy of Sciences · Tests: Anti-GPC3-IRDye800CW Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology NCT07303725n/a1 site📍 Palo Alto Palo Alto Veterans Institute for Research FDG PET-CT in Advanced Breast Cancer NCT07173868n/a1 site📍 Seoul Samsung Medical Center A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites📍 Birmingham📍 Birmingham📍 Birmingham Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046054, pembrolizumab Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver) NCT07665372NA19 sites📍 Phoenix📍 Los Angeles📍 San Francisco Johns Hopkins University · Tests: HIV D+/R+, HIV D-/R+ Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) NCT05870969n/a1 site📍 Shanghai Ruijin Hospital · Tests: Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT REGULUS: MRI-guided Adaptive SABR for Liver Cancers NCT07223307Phase 21 site📍 Palo Alto Stanford University · Tests: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer NCT07392567n/a1 site📍 Wuhan Tongji Hospital · Tests: Multimodal Deep Learning Prediction Model Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE Lenvatinib Plus Chemotherapy for pNET Liver Metastases NCT07835893Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Chemotherapy Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant NCT06725121Phase 1, Phase 22 sites📍 London📍 Toronto University Health Network, Toronto · Tests: Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT) Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354Phase 21 site📍 Wuhan Tongji Hospital · Tests: Tislelizumab plus Huaier granule AI-Assisted Non-Contrast CT for Multi-Cancer Screening NCT06632886NA1 site📍 Shanghai Guo ShiWei · Tests: AI-Assisted Non-Contrast CT for Multi-Cancer Screening Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma NCT06475118NA1 site📍 Reims CHU de Reims · Tests: Dynamometry measurement, myokine dosing, sarcopenia calculation
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy